AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) in a research report sent to investors on Friday, October 27th. HC Wainwright currently has a $5.00 target price on the specialty pharmaceutical company’s stock.

A number of other analysts have also issued reports on ACRX. Zacks Investment Research lowered shares of AcelRx Pharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, July 11th. Jefferies Group LLC restated a buy rating and set a $7.00 target price on shares of AcelRx Pharmaceuticals in a research report on Friday, July 14th. ValuEngine upgraded shares of AcelRx Pharmaceuticals from a sell rating to a hold rating in a research report on Monday, July 24th. Piper Jaffray Companies set a $3.00 price target on shares of AcelRx Pharmaceuticals and gave the company a hold rating in a report on Tuesday, July 25th. Finally, Cowen and Company reiterated a hold rating on shares of AcelRx Pharmaceuticals in a report on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. AcelRx Pharmaceuticals presently has a consensus rating of Hold and a consensus target price of $6.83.

Shares of AcelRx Pharmaceuticals (ACRX) traded up $0.02 during midday trading on Friday, reaching $1.97. 949,900 shares of the company were exchanged, compared to its average volume of 1,004,363. AcelRx Pharmaceuticals has a 1 year low of $1.55 and a 1 year high of $5.75. The company has a current ratio of 4.92, a quick ratio of 4.81 and a debt-to-equity ratio of -0.47.

ILLEGAL ACTIVITY NOTICE: “AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Given “Buy” Rating at HC Wainwright” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/11/11/acelrx-pharmaceuticals-acrx-buy-rating-reiterated-at-hc-wainwright.html.

In other AcelRx Pharmaceuticals news, CEO Vincent J. Angotti bought 15,000 shares of AcelRx Pharmaceuticals stock in a transaction that occurred on Thursday, August 24th. The shares were acquired at an average price of $3.00 per share, for a total transaction of $45,000.00. Following the acquisition, the chief executive officer now owns 15,000 shares of the company’s stock, valued at approximately $45,000. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, insider Pamela P. Palmer bought 10,000 shares of AcelRx Pharmaceuticals stock in a transaction that occurred on Tuesday, August 22nd. The shares were acquired at an average price of $2.95 per share, for a total transaction of $29,500.00. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 37,000 shares of company stock worth $112,280. 28.10% of the stock is owned by company insiders.

Several large investors have recently bought and sold shares of ACRX. Goldman Sachs Group Inc. acquired a new position in shares of AcelRx Pharmaceuticals during the 2nd quarter valued at $530,000. LMR Partners LLP purchased a new stake in AcelRx Pharmaceuticals during the 2nd quarter worth $319,000. Virtu KCG Holdings LLC increased its stake in AcelRx Pharmaceuticals by 600.9% during the 2nd quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock worth $255,000 after buying an additional 101,742 shares during the period. WealthTrust Axiom LLC increased its stake in AcelRx Pharmaceuticals by 50.0% during the 2nd quarter. WealthTrust Axiom LLC now owns 210,000 shares of the specialty pharmaceutical company’s stock worth $451,000 after buying an additional 70,000 shares during the period. Finally, Perennial Advisors LLC purchased a new stake in AcelRx Pharmaceuticals during the 3rd quarter worth $138,000. Institutional investors and hedge funds own 23.52% of the company’s stock.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply